Global /Taiwan /Healthcare /Biotechnology /6709

Advagene Biopharma Co., Ltd.

6709

• TPEX: 6709 • Delayed

26.20TWD -1.1%

0.8237 USD

As of 26 June 2026, Advagene Biopharma Co., Ltd. has a market cap of $49.47M USD, ranking #30592 globally and #1842 in Taiwan. It ranks #2762 in the Healthcare sector, and #532 in the Biotechnology industry.

Global Rank

30592

Country Rank

1842

Sector Rank

2762

Industry Rank

532

Key Stats

Market Cap

$49.47MUSD

1.57B TWD

Enterprise Value

$45.36MUSD

1.44B TWD

EBITDA (TTM)

-$2.22MUSD

-70.62M TWD

Net Income (TTM)

-$2.15MUSD

-68.29M TWD

PB Ratio

10.3

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Yu-Shen Hsu open_in_new

Employees

Founded

2006

Website

advagene.com.tw open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.1%	1.9%	-7.7%	-23%	-25%	-5.5%	52%	-13%	-46%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6709 昱厚生技股份有限公司 Ordinary Shares ISIN: TW0006709009 Shares Out.: Shares Outstanding: 68.38M¹ TV: TradingView: TPEX: 6709 SA: Stock Analysis: TPEX: 6709 YF: Yahoo Finance: 6709.TWO GF: Google Finance: TPEX: 6709 BA: Barron's: 6709 MS: Morningstar: ROCO: 6709	26.20 TWD	TV: TradingView: TPEX: 6709 SA: Stock Analysis: TPEX: 6709 YF: Yahoo Finance: 6709.TWO GF: Google Finance: TPEX: 6709 BA: Barron's: 6709 MS: Morningstar: ROCO: 6709

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Advagene Biopharma Co., Ltd.

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.43B 172.76B TWD 11K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.6B 50.93B TWD 3K%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.07B 34.04B TWD 2K%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$741.74M 23.59B TWD 1K%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$596.73M 18.98B TWD 1K%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$567.91M 18.06B TWD 1K%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 369K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 323K%	19.0	United States
argenx SE EBR: ARGX	$47.08B 41.39B EUR 95K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.15B 68.19T KRW 89K%	35.5	South Korea
CSL Ltd. ASX: CSL	$41.67B 60.27B AUD 84K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.63B 33.71B CHF 84K%	37.2	Switzerland

chevron_leftBack